Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
780 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03913936 | Young, Empowered & Strong (YES): The Young Women's Breast Cancer Study 2- Focus on Intervention Pilot | completed | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT04339062 | Cemiplimab in AlloSCT/SOT Recipients With CSCC(CONTRAC) | completed | Phase 1 / Phase 2 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT05366413 | Early Interventional Treatment for Cancer Pain | completed | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT02025010 | Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer | completed | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 15, 2025 | clinicaltrials |
| NCT03093428 | Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC | completed | Phase 2 | 45 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT03520790 | Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer | terminated | Phase 1 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06888089 | Deep Clinical Trajectory Modeling to Optimize Accrual to Cancer Clinical Trials | completed | N/A | 20,707 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04239040 | GVAX Plus Checkpoint Blockade in Neuroblastoma | terminated | Phase 1 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT05584540 | UNTIRE: Cancer-related Fatigue With Digital Treatment | withdrawn | N/A | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT02795858 | A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors | completed | Phase 2 | 43 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT03654716 | Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer | completed | Phase 1 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT02724878 | Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma | completed | Phase 2 | 65 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03636503 | Rituximab + Immunotherapy in Follicular Lymphoma | terminated | Phase 1 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT02853500 | Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver Malignancies | withdrawn | Phase 4 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT04197310 | Cabozantinib and Nivolumab for Carcinoid Tumors | completed | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT03032107 | A Study Of Pembrolizumab In Combination With Trastuzumab-DM1 | completed | Phase 1 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06246084 | INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy | completed | N/A | 76 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT04149704 | Videos for Advance Care Planning in Young Adults | completed | N/A | 102 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT05403801 | STAMP+CBT mHealth for Cancer Pain | completed | N/A | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06543511 | MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies | withdrawn | N/A | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Nov 22, 2024 | clinicaltrials |
| NCT02268851 | A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL | completed | Phase 1 | 45 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT04525183 | REVITALIZE: A Telehealth Intervention for Women With Advanced Ovarian Cancer and PARP Inhibitor-Related Fatigue | completed | N/A | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT01827787 | Eribulin in HER2 Negative Metastatic BrCa | completed | Phase 2 | 83 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT01921335 | ARRY-380 + Trastuzuamab for Breast w/ Brain Mets | completed | Phase 1 | 41 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT02113878 | Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck | completed | Phase 1 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT03422003 | Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma | active not recruiting | N/A | 400 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT05521178 | Cardiotoxicities in Patients Receiving BTKi | withdrawn | — | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Oct 15, 2024 | clinicaltrials |
| NCT03936465 | Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer | completed | Phase 1 | 41 | Dana-Farber Cancer InstituteOTHER | 2 | Oct 2, 2024 | clinicaltrials |
| NCT02375555 | Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM | completed | Phase 2 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT03692325 | Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia | completed | Phase 2 | 33 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT03638453 | Pilot Feasibility of the Pediatric Cancer Resource Equity (PediCARE) Intervention | completed | N/A | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03661723 | Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma | completed | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03777982 | Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT | terminated | Phase 3 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT00809588 | Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF) | completed | Phase 1 | 84 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT04485767 | RESIST-ADT (Androgen Deprivation Therapy) | completed | N/A | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT03244826 | Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation | completed | N/A | 404 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 16, 2024 | clinicaltrials |
| NCT04708860 | Feasibility of Fasting & Exercise in Pts With HR+ MBC | completed | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 16, 2024 | clinicaltrials |
| NCT00487305 | Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma | completed | Phase 1 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT02355340 | Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture | completed | — | 22 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT04497142 | Effect of Perampanel on Peritumoral Hyperexcitability in HGG | completed | Phase 1 / Phase 2 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06335745 | PediCARE Health Equity Intervention in High-Risk Neuroblastoma | withdrawn | N/A | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Aug 5, 2024 | clinicaltrials |
| NCT04129151 | Palbociclib + Ganitumab In Ewing Sarcoma | terminated | Phase 2 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT03455764 | MCS110 With BRAF/MEK Inhibition in Patients With Melanoma | completed | Phase 1 / Phase 2 | 6 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT01523977 | Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL(CRAD001NUS175T) | completed | Phase 1 | 22 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT03101254 | LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma | completed | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT05050305 | Marizomib Central Nervous System (CNS) | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT00542451 | Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer | completed | Phase 2 | 406 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03141671 | Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509) | unknown | Phase 2 | 345 | Dana-Farber Cancer InstituteOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT03225716 | A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia | terminated | Phase 1 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT02920996 | Merestinib In Non-Small Cell Lung Cancer And Solid Tumors | terminated | Phase 2 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 11, 2024 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials